期刊
FUTURE ONCOLOGY
卷 17, 期 29, 页码 3781-3785出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2021-0598
关键词
clinical trial; dostarlimab; endometrial cancer; GARNET; lay summary; plain language summary
类别
资金
- GlaxoSmithKline
This document summarizes the GARNET trial, which focused on treating patients with dMMR endometrial cancer with dostarlimab and showed efficacy in shrinking tumors in some patients. The percentage of participants experiencing side effects was low and within expectations for this type of treatment.
This document provides a short summary of the GARNET trial which was published in JAMA Oncology in October 2020. At the end of this document, there are links to websites where you can find more information about this study. The trial enrolled adult participants with advanced solid tumors. This report is restricted to patients with a particular type of endometrial cancer that has a deficient mismatch repair (dMMR) status. Patients received a trial treatment called dostarlimab (also known by the brand name Jemperli). In the US, dostarlimab is approved as a single therapy in adult patients with dMMR recurrent or advanced endometrial cancer that has progressed on or after platinum-based chemotherapy. In the EU, dostarlimab is approved as a single therapy in adult patients with recurrent or advanced dMMR/microsatellite instability-high (MSI-H) endometrial cancer that has progressed on or after treatment with a platinum-containing regimen. The GARNET trial looked at dostarlimab given intravenously to patients with dMMR endometrial cancer from 7 countries. The trial showed that dostarlimab was successful in shrinking the tumor in 42% of these patients. In general, the percentage of participants who experienced medical problems (referred to as side effects) was low and within expectations for this type of treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据